Myroslava Sharabun, Robert O'Connell, Howard Greller, Andrew P Smith
{"title":"Oral Ibuprofen Versus Intramuscular Ketorolac for Acute Musculoskeletal Back Pain in the Emergency Department: A Prospective Analysis.","authors":"Myroslava Sharabun, Robert O'Connell, Howard Greller, Andrew P Smith","doi":"10.1177/08971900251394098","DOIUrl":null,"url":null,"abstract":"<p><p>Ibuprofen and ketorolac are nonsteroidal anti-inflammatory drugs (NSAIDs) commonly used to treat acute back pain in the Emergency Department (ED). Data comparing pain relief between oral and intramuscular administration at their proposed ceiling doses is lacking. The aim of this study was to compare oral (PO) ibuprofen 400 mg to intramuscular (IM) ketorolac 10 mg for the treatment of acute, atraumatic, musculoskeletal back pain. This single-center, double-blind, double-placebo, randomized study compared PO ibuprofen 400 mg to IM ketorolac 10 mg for acute, atraumatic musculoskeletal back pain in adult patients presenting to an urban ED. Subjects were randomized to receive PO ibuprofen 400 mg suspension plus IM placebo injection or IM ketorolac 10 mg plus PO placebo suspension. The primary outcome was absolute reduction in pain score 1 hour after medication administration, as measured by visual analog scale (VAS). Secondary outcomes included rescue analgesia administration at 60 minutes and adverse drug reactions. The author's enrolled 93 patients; 47 in the ibuprofen group and 46 in the ketorolac group. VAS score reduction from baseline to 1 hour with ibuprofen or ketorolac was 35 vs 32, respectively (95% Confidence Interval: -8.03 to 15.03). Rescue analgesia administration at 60 minutes was similar between both groups; adverse reactions were reported in the ketorolac group only as pain at injection site in two patients. In this prospective analysis, PO ibuprofen 400 mg and IM ketorolac 10 mg provide comparable pain relief for the treatment of acute, atraumatic, musculoskeletal back pain.</p>","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"315-321"},"PeriodicalIF":1.0000,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of pharmacy practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/08971900251394098","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/11/6 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Ibuprofen and ketorolac are nonsteroidal anti-inflammatory drugs (NSAIDs) commonly used to treat acute back pain in the Emergency Department (ED). Data comparing pain relief between oral and intramuscular administration at their proposed ceiling doses is lacking. The aim of this study was to compare oral (PO) ibuprofen 400 mg to intramuscular (IM) ketorolac 10 mg for the treatment of acute, atraumatic, musculoskeletal back pain. This single-center, double-blind, double-placebo, randomized study compared PO ibuprofen 400 mg to IM ketorolac 10 mg for acute, atraumatic musculoskeletal back pain in adult patients presenting to an urban ED. Subjects were randomized to receive PO ibuprofen 400 mg suspension plus IM placebo injection or IM ketorolac 10 mg plus PO placebo suspension. The primary outcome was absolute reduction in pain score 1 hour after medication administration, as measured by visual analog scale (VAS). Secondary outcomes included rescue analgesia administration at 60 minutes and adverse drug reactions. The author's enrolled 93 patients; 47 in the ibuprofen group and 46 in the ketorolac group. VAS score reduction from baseline to 1 hour with ibuprofen or ketorolac was 35 vs 32, respectively (95% Confidence Interval: -8.03 to 15.03). Rescue analgesia administration at 60 minutes was similar between both groups; adverse reactions were reported in the ketorolac group only as pain at injection site in two patients. In this prospective analysis, PO ibuprofen 400 mg and IM ketorolac 10 mg provide comparable pain relief for the treatment of acute, atraumatic, musculoskeletal back pain.
布洛芬和酮酸是非甾体抗炎药(NSAIDs),通常用于治疗急诊科(ED)的急性背痛。比较口服和肌肉注射在其建议的上限剂量下缓解疼痛的数据是缺乏的。本研究的目的是比较口服(PO)布洛芬400mg与肌注(IM)酮罗拉酸10mg治疗急性、非创伤性、肌肉骨骼性背痛的效果。这项单中心、双盲、双安慰剂、随机研究比较了PO布洛芬400mg和IM酮洛拉酸10mg治疗急性、非创伤性肌肉骨骼性背痛的城市ED成年患者。受试者被随机分配接受PO布洛芬400mg混悬液加IM安慰剂注射或IM酮洛拉酸10mg加PO安慰剂混悬液。主要结局是在给药后1小时疼痛评分的绝对减少,用视觉模拟量表(VAS)测量。次要结局包括60分钟镇痛抢救和药物不良反应。作者入组了93例患者;布洛芬组47例,酮咯酸组46例。布洛芬或酮乐酸从基线到1小时的VAS评分降低分别为35 vs 32(95%置信区间:-8.03至15.03)。两组60分钟抢救镇痛给药效果相似;酮咯酸组仅有2例患者出现注射部位疼痛的不良反应。在这项前瞻性分析中,PO布洛芬400mg和IM酮洛酸10mg对急性、非创伤性、肌肉骨骼性背痛的治疗提供了相当的疼痛缓解。
期刊介绍:
The Journal of Pharmacy Practice offers the practicing pharmacist topical, important, and useful information to support pharmacy practice and pharmaceutical care and expand the pharmacist"s professional horizons. The journal is presented in a single-topic, scholarly review format. Guest editors are selected for expertise in the subject area, who then recruit contributors from that practice or topic area.